Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies

Tip Ranks
2025.11.18 14:26
portai
I'm PortAI, I can summarize articles.

Jefferies analyst Roger Song maintained a Buy rating on Kiniksa Pharmaceuticals with a price target of $58.00. Song, who covers the Healthcare sector, has an average return of -5.1% and a 37.50% success rate. The analyst consensus rating for Kiniksa Pharmaceuticals is Strong Buy with a $52.00 average price target.

Jefferies analyst Roger Song maintained a Buy rating on Kiniksa Pharmaceuticals today and set a price target of $58.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Cabaletta Bio, and Oruka Therapeutics. According to TipRanks, Song has an average return of -5.1% and a 37.50% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kiniksa Pharmaceuticals with a $52.00 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer